Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer Chief Executive Officer Albert Bourla said that vaccines are harder to get approved right now as Health Secretary ...

Pfizer could be entering a tougher regulatory climate as CEO Albert Bourla warned that vaccine approvals in the U.S. have ...

President Trump at 5p ET Friday will say that AstraZeneca has made a deal with the Trump administration to cut the prices of ...

GoodRx, an online platform that offers drug discount coupons to patients, is in talks with the government to participate in ...

U.S. drugmaker Pfizer Inc is hoping to rapidly roll out its experimental COVID-19 vaccine around Latin America soon after it gets emergency authorization in the United States, a senior executive said, ...

Pfizer Inc's experimental COVID-19 vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday, a major victory in the war against a virus that has killed over a ...

Journal Editorial Report: Trump unveils ‘Trump Rx’ and makes a deal with Pfizer. Pfizer CEO Albert Bourla earned $24.6 million in compensation last year. Despite his company’s sagging share price and ...

Over a weekend in late September, the team of Pfizer PFE-0.04%decrease; red down pointing triangle officials working with the Trump administration on drug prices got a message: Clear your schedules.

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...